Update: 6th and 7th extension projects to advance oncology candidate with global pharma company

Physiomics is pleased to announce that it has signed further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The 6th extension will cover predicting optimal regimens for follow-up compounds and in vitro to in vivo translation, whereas the 7th extension will predict optimal regimens for a candidate in an additional cancer indication

Read more